American Medical News' 55-year publishing run will come to a close this year, the AMA, its publisher, said today.
CMI/Compas says mobile-ad recall is low but growing, and that smartphones rule professional mobile use.
Publisher middleman DeepDyve has launched a five-minute "freemium" service that CEO William Park says saves researchers money, and prevents the hassle of buying off-target research. Publishers such as Wiley support the service through cross-promotions on their websites.
The most effective journal ads of the year included executions for Pradaxa, Humira and Conceptus' Essure Procedure, according to the Doctors' Choice Study.
Medscape founder Peter Frishauf, advertising metrics pioneer David Labson and Dorothy Philips, Ph.D., who blazed a trail for women in medical advertising, are MAHF's newest inductees.
Statistics show medical professionals are migrating toward iPads. Now, one medical journal publisher says, advertisers have followed.
Well before the FDA revoked Avastin's approval in breast cancer, Roche's Genentech unit deeply cut the professional media plan for the drug, the company said.
Four out of five ads analyzed in a study of physician-directed pharmaceutical advertising would definitely not pass FDA muster, or might have trouble doing so, said researchers. Their findings may have implications for the FDA, DDMAC and the "Bad Ad" program.
Is a medical journal ad for platelet-inhibition testing backed up by evidence that treatment guided by such testing can reduce the risk of clot formation?
In what could be seen as a positive sign of the times, the Association of Medical Media (AMM) announced the finalists for its 2010 Doctors' Choice Awards, which recognizes the best pharmaceutical journal ads, as chosen by physicians. The AMM established the awards in 2003, but did not give the awards last year, due to budgetary concerns.
Quadrant HealthCom united two titles - The Female Patient and OBG Management - under an alliance providing advertisers with a "ping-pong" opportunity for campaigns.
Sage, an international publisher of medical journals, books and electronic media, is shifting all of its 560-plus titles onto a new platform hosted by Stanford University Libraries' HighWire Press.
Healthy Advice Networks is betting docs need one more video screen to look at during office hours.
UK regulators vowed to investigate a medical journal ad for AstraZeneca's Seroquel that allegedly minimized weight gain data, a common side effect associated with atypical anti-psychotic drugs.
The FDA issued an untitled letter upbraiding Lilly for Cymbalta consumer and professional ads.
Cephalon has consolidated its oncology advertising business into Interpublic Group's Draftfcb.
Quadrant HealthCom purchased the journals division of Dowden Health Media from Lebhar-Friedman. Terms of the deal were not disclosed.
Medical advertising pioneer Frank J. Corbett, a founder of the Corbett Accel network, passed away at the age of 92.
King's launch of Embeda, a pain drug containing morphine, demonstrates that even supposedly abuse-resistant narcotic products need to take a careful approach in their marketing.
The FDA issued an untitled letter to J&J for a journal ad for its athlete's foot treatment Ertaczo Cream, saying the ad omits key risk info, broadens the indication and overhypes efficacy.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.